Olink to Report First Quarter 2021 Financial Results on May 20, 2021
Olink Holding AB (Nasdaq: OLK) will release its first-quarter 2021 financial results before market open on May 20, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Olink Holding AB (Nasdaq: OLK) will release its first-quarter 2021 financial results before market open on May 20, 2021. The management team will host a conference call at 8:00 a.m. ET to discuss these results. Investors can listen in by dialing the designated numbers based on their location. Olink specializes in proteomics and collaborates with biopharmaceutical companies and academic institutions to advance human biology understanding. Established in 2016, Olink is headquartered in Uppsala, Sweden, and operates across Europe, North America, and Asia.
Details
News Market Reaction – OLK
The recorded move for OLK in the trading session of this news was -5.06%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UPPSALA, Sweden, April 29, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK), a global leader in proteomics, today announced that it will release financial results for the first quarter of 2021 before the market open on Thursday, May 20, 2021. Company management will host a conference call to discuss financial results at 8:00 a.m. ET.
Investors interested in listening to the conference call may do so by dialing (833) 562-0120 for domestic callers or (661) 567-1096 for international callers, followed by Conference ID: 5167217. A live and archived webcast of the event will be available on the “Investors” section of the Olink website at investors.olink.com.
About Olink
Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.
Contacts
Stina Thorman
stina.thorman@olink.com
+46707187354
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.